1. pS2--a new cytosolic protein recognized by monoclonal antibodies as a marker of hormone sensitivity in breast cancer.
- Author
-
Correale M, Abbate I, Paradiso A, Schittulli F, Dragone CD, Tedone T, Gargano G, Catino AM, Musci MD, and De Lena M
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms physiopathology, Carcinoma physiopathology, Cytosol chemistry, Estrogens physiology, Female, Humans, Immunoradiometric Assay, Middle Aged, Multiple Chemical Sensitivity, Prognosis, Receptors, Estrogen physiology, Receptors, Progesterone physiology, Trefoil Factor-1, Tumor Suppressor Proteins, Antibodies, Monoclonal immunology, Antibodies, Monoclonal metabolism, Biomarkers analysis, Breast Neoplasms diagnosis, Carcinoma diagnosis, Neoplasm Proteins blood, Neoplasm Proteins immunology, Proteins
- Abstract
Using a new immunoradiometric assay (ELSA pS2 Cis-France), a total of 200 cytosols obtained from primary breast tumors were examined for pS2 content, which is an estrogen-regulated protein actually studied as a marker of hormone sensitivity and favorable prognostic factor in breast cancer. In our patient group, the median pS2 value corresponding to 5.3 ng/mg of cytosolic proteins was used as cutoff. pS2 content was not related to menopause status, tumor size, or nodal involvement, whereas a positive correlation was found between pS2 and ER/PgR status. Moreover, the association of pS2 with steroid receptors seems to identify subgroups of patients better than ER/PgR alone.
- Published
- 1993
- Full Text
- View/download PDF